@misc{Długosz-Danecka_Monika_Early_2014,
 author={Długosz-Danecka, Monika},
 address={Kraków},
 howpublished={online},
 year={2014},
 school={Wydział Lekarski},
 language={pol},
 abstract={One of the most commonly used first line regimens is CHOP protocol.It’s efficacy depends largely from doxorubicin: an anthracyclineantibiotic, responsible for marked cardiovascular toxicity. Clinicalsymptoms of doxorubicin cardiotoxicity occur late in the diseasecourse. At this stage however, the process is already non-reversible.Early diagnosis, before the eventual damage of cardiomyocytes,possible by demonstrating diastolic dysfunction, allows introducingefficient cardioprotective therapy preventing further cardiac damage.Primary and secondary targets of the work were: early identification ofpatients with high-risk of cardiotoxicity and analysis of primaryeffectiveness of cardioprotective strategies (non-pegylated liposomaldoxorubicin, cardioprotective drugs) in high risk patients. Presenteddata are consistent: NT-proBNP, spatial QRS-T angle analysis andechocardiographic assessment of diastolic dysfunction of the leftventricle allow for early detection of doxorubicin cardiotoxicity, at thereversible stage, allowing for efficient prophylaxis before irreversiblecardiomyocyte damage occurs. Primary cardioprotection withliposomal doxorubicin, in combination with the beta-adrenolytic drugsand/or ACE-inhibitor allowed for effective oncological treatment ofpatients with increased cardiovascular risk, without development ofcardiotoxic complications.},
 title={Early detection of the increased risk of cardiovasculartoxicity in patients undergoing anthracycline-based CHOPregimen},
 type={Praca doktorska},
 keywords={anthracyclines, cardiotoxicity, cardioprotection, echocardiography, CHOP},
}